The ACCURE-trial: the effect of appendectomy on the clinical course of ulcerative colitis, a randomised international multicenter trial (NTR2883) and the ACCURE-UK trial: a randomised external pilot trial (ISRCTN56523019). Issue 1 (December 2015)

• Record Type: Journal Article
• Authors: Gardenbroek, Tjibbe; Pinkney, Thomas; Sahami, Saloomeh; Morton, Dion; Buskens, Christianne; Ponsioen, Cyriel; Tanis, Pieter; Löwenberg, Mark; van den Brink, Gijs; Broeders, Ivo; Pullens, Paul; Seerden, Tom; Boom, Maarten; Mallant-Hent, Rosalie; Pierik, Robert; Vecht, Juda; Sosef, Meindert; van Nunen, Annick; van Wagensveld, Bart; Stokkers, Pieter; Gerhards, Michael; Jansen, Jeroen; Acherman, Yair; Depla, Annekatrien; Mannaerts, Guido; West, Rachel; Iqbal, Tariq; Pathmakanthan, Shrikanth; Howard, Rebecca; Magill, Laura; Singh, Baljit; Htun Oo, Ye; Negpodiev, Dmitri; Dijkgraaf, Marcel; RAM D'Haens, Geert; Bemelman, Willem;
• Is Part Of: BMC surgery. Volume 15:Issue 1(2015)
• Page Start: 1
• Page End: 7
• Publication Date: 2015-12
• Subjects: Inflammatory bowel disease -- Ulcerative colitis -- Appendectomy -- Surgery -- Disease course; Surgery -- Periodicals; 617.005
• DOI: 10.1186/s12893-015-0017-1
• Languages: English
• ISSNs: 1471-2482

Abstract

Abstract Background Over the past 20 years evidence has accumulated confirming the immunomodulatory role of the appendix in ulcerative colitis (UC). This led to the idea that appendectomy might alter the clinical course of established UC. The objective of this body of research is to evaluate the short-term and medium-term efficacy of appendectomy to maintain remission in patients with UC, and to establish the acceptability and cost-effectiveness of the intervention compared to standard treatment. Methods/Design These paired phase III multicenter prospective randomised studies will include patients over 18 years of age with an established diagnosis of ulcerative colitis and a disease relapse within 12 months prior to randomisation. Patients need to have been medically treated until complete clinical (Mayo score <3) and endoscopic (Mayo score 0 or 1) remission. Patients will then be randomised 1:1 to a control group (maintenance 5-ASA treatment, no appendectomy) or elective laparoscopic appendectomy plus maintenance treatment. The primary outcome measure is the one year cumulative UC relapse rate - defined both clinically and endoscopically as a total Mayo-score ≥5 with endoscopic subscore of 2 or 3. Secondary outcomes that will be assessed include the number of relapses per patient at 12 months, the time to first relapse, health related quality of life and treatment costs, and number of colectomies in each arm. Discussion The ACCURE and ACCURE-UK trials will provide evidence on the role and acceptability of appendectomy in the treatment of ulcerative colitis and the effects of appendectomy on the disease course. Trial registration NTR2883 ;ISRCTN56523019